Pancreatic cancer is the 14 th most common cancer worldwide and imposes a huge burden on global healthcare. Moreover, it is associated with poor survival rates compared to cancers of other anatomical origins. The median survival is only nine months, and less than 10% of people survive five years or more from the time of diagnosis. Hence, early diagnosis and therapeutic intervention for pancreatic cancer are crucial.
Weight loss, hyperglycemia, and diabetes are known signs of pancreatic cancer. Researchers have now identified body mass index (BMI) and glycated hemoglobin (HbA1c) as biomarkers that can predict its incidence three years before patients are diagnosed with pancreatic cancer. BMI and HbA1c of a total of 8777 pancreatic cancer patients were compared with that of age-matched controls for three years, and it was observed that changes in these parameters began three years before…
